WO2006113425A1 - Process for preparing quetiapine fumarate - Google Patents

Process for preparing quetiapine fumarate Download PDF

Info

Publication number
WO2006113425A1
WO2006113425A1 PCT/US2006/014049 US2006014049W WO2006113425A1 WO 2006113425 A1 WO2006113425 A1 WO 2006113425A1 US 2006014049 W US2006014049 W US 2006014049W WO 2006113425 A1 WO2006113425 A1 WO 2006113425A1
Authority
WO
WIPO (PCT)
Prior art keywords
quetiapine
reaction
solvent
thiazepine
toluene
Prior art date
Application number
PCT/US2006/014049
Other languages
French (fr)
Inventor
Vinod Kumar Kansal
Kanhaiya Lal
Suhail Ahmad
David Leonov
Original Assignee
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Usa, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US67217505P priority Critical
Priority to US60/672,175 priority
Priority to US67709105P priority
Priority to US60/677,091 priority
Priority to US68014005P priority
Priority to US60/680,140 priority
Application filed by Teva Pharmaceutical Industries Ltd., Teva Pharmaceutical Usa, Inc. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of WO2006113425A1 publication Critical patent/WO2006113425A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D281/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02Seven-membered rings
    • C07D281/04Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16[b, f]-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Abstract

Provided is a novel synthesis of quetiapine, and pharmaceutically acceptable salts thereof, in which an alkali metal halide or siliyl halide is included in the reaction mixture.

Description

PROCESS FOR PREPARING QUETIAPINE FUMARATE
RELATED APPLICATIONS
The present application claims the benefit of the April 14, 2005 filing date of the U.S. Provisional Patent Application 60/672,175, the May 2, 2005 filing date of the U.S. Provisional Patent Application 60/677,091 and the May 11, 2005 filing date of the U.S. Provisional Patent Application 60/680,140.
FIELD OF THE INVENTION
The present invention relates to synthesis of quetiapine and pharmaceutically acceptable salts thereof.
BACKGROUND OF THE INVENTION
Quetiapine,2-(2-(4-dibenzo[δ,/| [ 1 ,4]thiazepin- 11 -yl- 1 - piperazmyl)ethoxy)ethanol, having the following chemical structure:
Figure imgf000002_0001
Quetiapine is a psychoactive organic compound that acts as an antagonist for multiple neurotransmitter receptors in the brain and acts as an antipsychotic agent reportedly useful for treating, among other things, schizophrenia. Merck Index, 13th Ed., 8130 (2001). This drug, having the CAS number: 111974-69-7, was approved under the trademark Seroquel®, by the U.S. Food and Drug Administration and is available from the innovator, AstraZeneca PLC. Quetiapine can be made, for example, as taught in the U.S. Patent No. 4,879,288, incorporated in its entirety herein by reference.
As taught in the '288 patent, quetiapine can be made via reaction of formula I, 11-piperazinyl dibenzo[b,f]-[l,4]thiazepine hydrochloride and about a 2 molar equivalent of formula II, l-(2-hydroxyethoxyethyl)piρerazine,
Figure imgf000003_0001
II
wherein the reaction time is about 30 hours, the yield is about 77%, and puritfication is by flash chromotpgraphy.
Thus, there is a need in the art for an improved process for making quetiapine and salts thereof from 11-piperazinyl dibenzo[b,fl-[l,4]thiazepine and 2-(2- chloroethoxy)ethanol using less than a 2 molar equivalent of 2-(2- chloroethoxy)ethanol with respect to 11-piperazinyl dibenzo[b,fl-[l,4]thiazepine, a shorter reaction time, and affording a quetiapine product that contains a lower level of impurities (such as the unreacted starting material) so that the process can be easily, conveniently, and inexpensively applied on an industrial scale.
SUMMARY OF THE INVENTION
In one embodiment, the present invention provides a method of preparing quetiapine comprising: reacting ll-chlorodibenzo[ό,/|[l,4]-thiazepine with l-(2- hydroxyethoxyethyl)piperazine in a reaction solvent selected from the group consisting of: C5 to C12 saturated or aromatic hydrocarbons, C1 to C4 alcohols, C1 to C4 alkyl esters, C2 to C8 ketones, C2 to C8 linear, branched or cyclic or acyclic ethers, C3 to C10 alkyl esters, and Ci to C4 alkyl nitriles, or mixtures thereof, in the presence of at least one organic or inorganic base, and an alkali metal halide or a silyl halide to obtain quetiapine; and recovering the obtained quetiapine.
In another aspect, the present invention relates to a method of preparing a pharmaceutically acceptable salt of quetiapine comprising combining an acid with the quetiapine prepared according to the process described above; and recovering the obtained pharmaceutically acceptable salt of quetiapine. Preferably, the pharmaceutically acceptable salt is quetiapine fumarate, and the acid is fumaric acid. In another embodiment, the present invention provides a method for preparing quetiapine comprising: reacting ll-chlorodiberizo[Z?j][l,4]-thiazepine with l-(2- hydroxyethoxyethyl)piperazine in a reaction solvent selected from the group consisting of: C5 to C12 saturated or aromatic hydrocarbons, C1 to C4 alcohols, C1 to C4 alkyl esters, C2 to C8 ketones, C2 to C8 linear, branched or cyclic or acyclic ethers, C3 to C10 alkyl esters, and C1 to C4 alkyl nitriles, or mixtures thereof, in the presence of at least one organic or inorganic base, and a phase transfer catalyst; and recovering the obtained quetiapine.
In another aspect, the present invention relates to a method of preparing a pharmaceutically acceptable salt of quetiapine comprising combining an acid with the quetiapine prepared according to the process described above; and recovering the obtained pharmaceutically acceptable salt of quetiapine. Preferably, the pharmaceutically acceptable salt is quetiapine furnarate, and the acid is fumaric acid.
DETAILED DESCRIPTION OF THE INVENTION
In one embodiment, the present invention provides a method of preparing quetiapine including the steps of: reacting l l-chlorodibenzo[ό,/][l,4]-thiazepme, herein "I" with l-(2-hydroxyethoxyethyl)piperazine, herein "II", in a reaction solvent selected from the group consisting of: C5 to C12 saturated or C6to C12 aromatic hydrocarbons, C1 to C4 alcohols, C1 to C4 alkyl esters, C2 to C8 ketones, C2 to C8 linear, branched or cyclic or acyclic ethers, C3 to C10 alkyl esters, and C1 to C4 alkyl nitriles, or mixtures thereof, in the presence of at least one organic or inorganic base, and, particularly, a halide compound that is an alkali metal halide or a silyl halide to obtain quetiapine; and, optionally, recovering the obtained quetiapine. Alkali metal halides useful in the practice on the present invention include alkali metal fluorides, iodides, or bromides. Alkali metal iodides are preferred. Silylhalides can also be used in the practice of the method of the present invention. Potassium iodide (KI) is a particularly preferred alkali metal halide for use in the practice of the present invention. The alkali metal or silylhalide is used in a molar ratio of about 0.2 or greater relative to the moles of I used.
In another embodiment, the present invention provides a method for preparing quetiapine comprising: reacting ll-chlorodibenzo[b,/J[l,4]-thiazepine with l-(2- hydroxyethoxyethyl)piperazine in a reaction solvent selected from the group consisting of: C5 to C12 saturated or aromatic hydrocarbons, C1 to C4 alcohols, C1 to C4 alkyl esters, C2 to C8 ketones, C2 to C8 linear, branched or cyclic or acyclic ethers, and C1 to C4 alkyl nitriles, or mixtures thereof, in the presence of at least one organic or inorganic base, and a phase transfer catalyst; and, optionally, recovering the obtained quetiapine.
Suitable phase transfer catalysts are ammonium salts such as tricaprylylmethylammonium chloride (Aliquat.RTM. 336), tetra-n-butylammonium bromide ("TBAB"), benzyltriethylammonium chloride ("TEBA"), cetyltrimethylammonium bromide, cetylpyridinium bromide, N-benzylquininium chloride, tetra-n-butylammonium chloride, tetra-n-butylammonium hydroxide, tetra- n-butylarnmonium iodide, tetra-ethylammonium chloride, benzyltributylammonium bromide, benzyltriethylammonium bromide, hexadecyltriethylanmuonium chloride, tetramethylammonium chloride, hexadecyltrimethyl ammonium chloride, and octyltrimethylammonium chloride. More preferred phase transfer catalysts are Aliquat.RTM. 336, TBAB, TEBA and mixtures thereof, the most preferred being Aliquat.RTM. 336 Inorganic bases useful in the practice of the present invention include alkali metal carbonates or hydroxides, for example potassium bi/carbonate, sodium bi/carbonate, or sodium hydroxide, cesium carbonate/hydroxide. Metal carbonate is a preferred inorganic base for use in the practice of the present invention.
When quetiapine is to be isolated, the reaction mixture is cooled to a convenient working temperature, for example room temperature, and combined with aqueous non-oxidizing acid (e.g. HCl). The layers are separated and the aqueous phase optionally washed and the organic layers combined. The combined organic layers are concentrated to afford quetiapine. The quetipine can be recrystallized from a suitable solvent, for example ethyl acetate.
In the processes described above, the reaction temperature is about room temperature (typically 22° to 27° C) to about reflux temperature, preferably at about reflux temperature. Preferably, the reaction solvent is a halogenated hydrocarbon or alkyl ester. Toluene and xylenes are particularly preferred reaction solvents, but alkyl alcohols (e.g. n-butanol) are also very suitable as reaction solvents in the practice of the present invention. Preferably, the ll-chlorodibenzo[6,/][l,4]thiazepine (I) is in the amount of about 1 to about 1.5, preferably about 1 to about 1.2, molar equivalents (based on the moles of I) of l-(2-hydroxyethoxy)ethyl piperazine (II).
Inorganic bases useful in the practice of the present invention are well known to the skilled artisan and include alkali metal carbonates, alkali metal bicarbonates, and alkali metal hydroxides. Organic bases usefull in the practice of the present invention include mono-, di- or TTi-(C1 to C4 alkyl)amines such as N5N- dimethylanaline and N,N-diisopropyl ethyl amine. Tertiary amines are preferred organic bases for use in the practice of the present invention. The organic or inorganic base is preferably used in a molar amount between about 1 and about 3, more preferably about 2, times the molar amount of I used in the reaction.
Preferably, the resulting crude quetiapine in the processes described above can then be isolated. Isolation is preferably by cooling the reaction mixture to a convenient temperature, for example room temperature. The optionally cooled reaction mixture is then treated with a nonoxidizing inorganic acid, preferably a mineral acid, for example hydrochloric acid. The inorganic acid can be and preferably is used as its aqueous solution. When an aqueous solution of a nonoxidizing acid is used, a two-phase mixture is obtained if preferred reaction solvents are used. The phases, when present, are separated and the aqueous phase is basified with an inorganic base such as a metal hydroxide or carbonate. The basified aqueous phase is extracted with an organic solvent, especially an organic solvent useful as a reaction solvent. The quetiapene base is obtained after removing the organic solvent, for example by distilling-off the solvent. Prior to isolation, the separated aqueous phase can be extracted with a reaction solvent that is the same or different from the solvent used in the first step, and the extract combined with the separated non-aqueous phase, whereafter the product is isolated from the combined reaction mixture and extracts, if any. By this process a purity of more than 90area% as measured by high pressure liquid chromatography, more preferably more than 95area% as measured by HPLC and most preferably more than 97area% as measured by HPLC, without the need for subjecting the crude product to purification by, for example, flash chromatography.
Reaction times of 20 hours or less, preferably about 10 to about 14 hours, are readily achievable in preferred embodiments of the present invention. The skilled artisan will know to monitor and adjust the reaction time by, for example, monitoring the disappearance of the limiting reagent, compound I in preferred embodiments, using a suitable technique, for example thin layer chromatography, gas-liquid chromatography, or high pressure liquid chromatography, to mention just three.
In another aspect, the present invention relates to a method of preparing a pharmaceutically acceptable salt of quetiapine comprising combining an acid with the quetiapine prepared according to the processes described above; and recovering the obtained pharmaceutically acceptable salt of quetiapine. Preferably, the pharmaceutically acceptable salt is quetiapine fumarate, and the acid is fumaric acid.
The general reaction scheme for preparing quetiapine fumarate is as follows:
Figure imgf000007_0001
In another embodiment of the present invention, a method is presented of preparing quetiapine and pharmaceutically acceptable salts thereof, preferably the hemi fumarate salt, comprising reacting ll-chlorodibenzo[6j][l,4]-thiazepine (I) with l-(2-hydroxyethoxyethyl)piperazine in a reaction solvent selected from the group consisting of: C5 to C12 saturated or aromatic hydrocarbon, C1 to C4 alcohol, C1 to C4 alkyl esters, C2 to C8 ketones, C2 to C8 linear, branched or cyclic or acyclic ethers, C3 to C10 alkyl esters, and C1 to C4 alkyl nitrile, in the presence of at least one organic or inorganic base, and a phase transfer catalyst. Preferably, the resulting quetiapine can then be isolated by acidification and extraction to obtain a purity of more than 90area% as measured by HPLC, more preferably more than 95area% as measured by HPLC and most preferably more than 97area% as measured by HPLC.
The crude product isolated from the reaction is sufficiently pure, typically > 97 area-% pure as measured by high pressure liquid chromatography, to be used in subsequent processing, for example conversion to a pharmaceutically acceptable salt, especially the hemifumarate, without the need for subjecting the crude product to purification by, for example, flash chromatography.
Preferably, the quetiapine fumarate is made by a one-pot synthesis, i.e., fumaric acid is combined directly with quetiapine prepared by processes of the invention without first having to isolate the quetiapine. The present invention in certain of its embodiments is illustrated in the following non-limiting examples. In the examples, "HPLC area-%" refers to purity on an area percent basis as determined from the area under the peaks in the HPLC chromatogram.
ANALYTICAL Quetiapine can be analyzed by the following HPLC method.
1: Acetonitrile (HPLC grade)
2: Water (HPLC grade)
3: Ammonium acetate (AR grade)
4: Ammonia (AR grade) 5: Acetic acid (AR grade)
Preparation of Buffer
Weigh accurately about 3.08 gm ( 0.04M) ammonium acetate in water add 2.0 ml of
25% ammonium hydroxide per 1000ml of buffer and mix. pH of the buffer should not be less than 9.2.Change the buffer daily.
Eluent A : Buffer Eluent B : Acetonitrile Diluent
Acetonitrile.
Chromatographic conditions
Column : Xterra RP8 , 3.5μ, 150 x 4.6mm, Waters
Flow : 1.5 ml/min Injection volume : 20 μl Column temperature '. 45 °C
Detector UV at 250nm
Autosampler Temp : 10°C
Gradient Programming:
Time % Eluent A %Eluent B
0 75 25
25 75 25
60 22 78
61 75 25
70 75 25 Before starting an analysis, wash the column for 30min with the following eluent : Eluent A20%: Eluent B 80%.
Preparation of system suitability solution
Prepare a mixture of about l.Omg/ml of Quetiapine fumarate and 0.002mg/ml of DBTP in diluent. Evaluation of System Suitability Test
Inject 20μl of system suitability solution.
A resolution factor between DBTP and Quetiapine peaks of not less than 7.0 should be achieved.
Typical retention times are ~ 17.5 minutes for DBTP and ~ 25.0 minutes for Quetiapine.
Preparation of sample solution
Prepare about lmg/ml solution of Quetiapine Base sample.
Procedure
Inject diluent as a blank. Inject sample solution into the chromatograph, continuing the chromatogram for whole gradient profile.Determine the area of all peaks using suitable integrator.
Disregard any peak eluting till 2min and any peak from the diluent. Disregard any peak less than 0.05%.
Calculation
„ . τ . , Area of impurity in the sample , , i Λ « % Impurity = X 100
Sum of area of all peaks in the chromatogram Note:
DBT : Di benzo[b,f][l,4]thiazepine-ll(10H)-one.
CDBT: Chloro dibenzo[b.f][l,4]thiazepine-ll(10H)-one.
Quetiapine hemifumarate
Reagents
1: Acetonitrile (HPLC grade)
2: Ammonium acetate (AR grade)
3 : Ammonium hydroxide (AR grade) 4: Acetic acid (AR grade) Preparation of Buffer
Prepare 0.04 M Ammonium acetate in water and add 2.0 ml of 25% ammonium hydroxide per 1000ml of buffer solution . pH of the buffer should not be less than 9.2.Change the buffer daily.
Eluent A : Buffer
Eluent B : Acetonitrile (gradient grade)
Chromatographic conditions
Column: XTerra RP8 , 3.5μ, 150 x 4.6mm,Waters
Flow 1.5 ml/min
Sample Volume 20 μl
Detector 250nm
Column temperature 45 °C Gradient Programming
Figure imgf000011_0001
Equilibration time : 8 minutes
Before starting an analysis, wash the column for 30 min with the following eluent : Eluent A20%: Eluent B 80%.Mobile phase composition and flow rate may be varied in order to achieve the required system suitability.
Preparation of system suitability solution
Prepare a mixture of about l.Omg/ml of Quetiapine fumarate standard and 0.002mg/ml of DBTP standard in diluent.
System Suitability Test
Inject system suitability solution.
A resolution factor between DBTP and Quetiapine peaks of not less than 7.0 should be achieved.
Typical retention times are ~ 17.5 minutes for DBTP and ~ 25.0 minutes for Quetiapine. Column efficiency for Quetiapine peak of not less than 10000 should be achieved.
Preparation of sample solution
Prepare accurately, lmg/ml solution of Quetiapine fumarate sample in diluent.
Procedure
Inject the sample solutions into the chromatograph, continuing the chromatogram for whole gradient profile.
Determine the area of all peaks using suitable integrator.
Disregard any peak eluting till 2 min and any peak from the injection of diluent. Disregard peaks less than 0.02% area Calculation a.) Calculate contents of QTP-triether,QTP-desethanol and DBTP-ethyl identified by RRT and DBTP identified by SST,according to their relative response factor (F).
Response factor of known impurity b —
Response factor of QTP
F = 0.62 for QTP-triether (RRT 0.32)
F = 1.2 for DBTP (RRT 0.72)
F = LO for QTP-desethanol (RRT 0.84)
F = Ll for DBTP-ethyl (RRT 1.5)
Known impurities are calculated as following:
Area of impurity / F in sample
% impurity known =
Area of QTP + Area of other peaks + known peaks / F
b.) Calculate any other impurities as follows:
Area of impurity i in sample % impurity i =
Area of QTP + Area of other peaks + known peaks / F
RL is 0.05%
DL is 0.02% '
Abbreviation:
DBTP : Dibenzo[b,fJ[l,4] thiazepine,ll-(l-piperazine)
QTP : Quetiapine Fumarate
QTP-desethanol : 2-[4-(dibenzo[b,fj[l,4] thiapin-l l-yl)piperazin-l-yl)]ethanol
QTP-triether: 2-(2-[4-(dibenzo[b,fJ[l,4] thiaρin-1 l-yl)ρiρerazin-l-yl)]triethoxyethanol DBTP-ethyl: 4-Ethyl(dibenzo[b3fJ[l,4]thiapin -ll-yl)piperazin -1-yl EXAMPLES
Example 1: Preparation of ll-[4-[2-(2-Hydroxyethoxy)ethyl]-l- piperaziήyl]dibenzo[b,f][l,4]thiazepine A 2 liter round bottom flask equipped with stirring rod, thermo pocket, reflux condenser and nitrogen inlet was charged with 50gm (0.2 moles) of 11- chlorodibenzo[b,f][l,4]-thiazepme (I), 500 cc toluene and the mixture was stirred for 15 min. at room temperature. The resulting solution was combined with 39 gm (0.22 mole) of l-(2-hydroxyethoxy)ethylpiperazine (II), 56.2 gm (0.40 mole) of potassium carbonate and 16.89gm (0.10 mole) of potassium iodide. The reaction mixture was heated at gentle reflux for 12 hrs and a sample of the reaction mixture was analyzed by HPLC. The analysis revealed that less than 1% of the starting material remained. The reaction mixture was cooled to room temperature and combined with 1000 cc IN hydrochloric acid solution to get a pH in between 1 to 2. The layers were separated and the aqueous layer was diluted with 500 cc toluene and pH was adjusted between 8 to 9 by addition of sodium carbonate. The layers (aqueous and nonaqueous reaction solvent toluene) were separated and the aqueous layer was extracted with 500 cc toluene. The organic (toluene) layers were combined and washed with 2 x 500 cc of water. The reaction solvent (toluene) was distilled-off under vacuum at 70 to 80°C to afford 60 gm oil. HPLC area %: 99.5
Example 2: Preparation of ll~[4-[2-(2-Hydroxyethoxy)ethyl]-l- piperazinyl]dibenzo[b,fj[l,4]thiazepine
A 2 liter round bottom flask equipped with stirring rod, thermo pocket, reflux condenser and nitrogen inlet was charged with 50gm (0.2 moles) of 11- chlorodibenzo[b,fj[l,4]-thiazepine (I) and 500 cc xylene and the mixture was stirred for 15 min. at room temperature. The resulting solution was combined with 39 gm (0.22 mole) of l-(2-hydroxyethoxy)ethylpiperazine, 56.2 gm (0.40 mole) of potassium carbonate and 16.89gm (0.10 mole) of potassium iodide. The reaction mixture was heated at gentle reflux for 12 hrs and a sample of the reaction mixture was analyzed by HPLC. The analysis revealed that less than 1% of starting material I remained. The reaction mixture was cooled to room temperature and treated with 1000 cc IN hydrochloric acid solution to get a pH in between 1 to 2. The layers were separated and the aqueous layer was agitated with 500 cc xylene and the pH was adjusted between 8 to 9 by addition of sodium carbonate. The layer s were separated and the aqueous layer was extracted with 500 cc xylene. The organic (xylene reaction solvent) layers were combined and washed with 2 x 500 cc of water. The solvent was distilled-off under vacuum at 70 to 80° C to afford 60 gm oil. HPLC area %: 99.5 Example 3: Preparation of ll-[4-[2-(2-Hydroxyethoxy)ethyl]-l- piperazinyl] dibenzo [b,fj [1 ,4] thiazepine
A 2 liter round bottom flask equipped with stirring rod, thermo pocket, reflux condenser and nitrogen inlet was charged with 50gm (0.2 moles) of 11- chlorodibenzo[b,fj[l,4]-thiazepine and 500 cc n-butanol and the mixture was stirred for 15 min. at room temperature. The resulting solution was combined with 39 gm (0.22 mole) of l-(2-hydroxyethoxy)ethylpiperazine, 56.2 gm (0.40 mole) of potassium carbonate and 16.89gm (0.10 mole) of potassium iodide. The reaction mixture was heated at gentle reflux for 12 hrs and a sample of the reaction mixture was analyzed by HPLC. The analysis revealed that starting material remains less than 1% . The reaction mixture was cooled to room temperature and treated with 1000 cc IN hydrochloric acid solution to get a pH in between 1 to 2. The layers (aqueous and nonaqueous reaction solvent) were separated and the aqueous layer was extracted with 500 cc toluene and pH was adjusted between 8 to 9 by addition of sodium carbonate. The layers were separated and aqueous layer was again extracted with 500 cc toluene. The organic layers (n-butanol and toluene) were combined and washed with 2 x 500 cc of water. The solvent was distilled under vacuum at 70 to 80°C to afford 47.5 gm oil. HPLC area %: 98.9
Example 4: Preparation of ll-[4-[2-(2-Hydroxyethoxy)ethyl]-l- piperazinyl] dibenzo [b,fj [1 ,4] thiazepine A l liter round bottom flask equipped with stirring rod, thermo pocket, reflux condenser and nitrogen inlet was charged with lOgm (0.04 moles) of 11- chlorodibenzo[b,fj[l,4]-thiazepine,100 cc toluene and the mixture was stirred for 15 min. at room temperature. The resulting solution was combined with 7.7 gm (0.044 mole) of l-(2-hydroxyethoxy)ethylpiperazine, 8.5 gm (0.08 mole) of sodium carbonate and 1.6 gm (0.01 mole) of sodium iodide. This reaction mixture was heated at gentle reflux for 15 hrs and the sample was analyzed by HPLC. The analysis revealed that starting material remains less than 1%. The reaction mixture was cooled to room temperature and treated with 175 cc IN hydrochloric acid solution to get a pH in between 1 to 2. The layers were separated and the aqueous layer was diluted with 100 cc toluene and pH was adjusted to about 8 to 9 using sodium carbonate. The layer s were separated and aqueous layer was extracted with 100 cc toluene. The organic layers were combined and washed with 2 x 100 cc of water. The solvent was distilled under vacuum at 70 to 80°C to afford 11 gm oil. HPLC area %: 98.3%
Example 5 (Comparative): Preparation of ll-[4-[2-(2-Hydroxyethoxy)ethyl]-l- piperazinyl] dibenzo [b,fj [1 ,4] thiazepine
A 1 liter round bottom flask equipped with stirring rod, thermo pocket, reflux condenser and nitrogen inlet was charged with lOgm (0.04 moles) of 11- chlorodibenzo[b,fj[l,4]-thiazepine, and 100 cc toluene and the mixture was stirred for 15 min. at room temperature. The resulting solution was combined with 7.0 gm
(0.04 mole) of l-(2-hydroxyethoxy)ethylpiperazine, and 3.2 gm (0.08 mole) of sodium hydroxide . This reaction mixture was heated at gentle reflux for 20 hrs and the sample was analyzed by HPLC. The analysis revealed that starting material remains less than 1%. The reaction mixture was cooled to room temperature and treated with 70 cc IN hydrochloric acid solution to get a pH in between 1 to 2. The layers were separated and the aqueous layer was diluted with 100 cc toluene and pH was adjusted to about 8 to 9 using sodium carbonate. The layers were separated and aqueous layer was extracted with 100 cc toluene. The organic layers were combined and washed with 2 x 100 cc of water. The solvent was distilled under vacuum at 70°C to 80°C to afford 12gm oil. HPLC area %: 66.47%
Example-6: Preparation of ll-[4-[2-(2-Hydroxyethoxy)ethyl)-l- piperazinyl] dibenzo [b,fj [1 ,4] thiazepine A l liter round bottom flask equipped with stirring rod, thermo pocket, reflux condenser and nitrogen inlet was charged with lOgm (0.04 moles) of 11- chlorodibenzo[b,fj[ 1,4] -thiazepine, 100 cc toluene and the mixture was stirred for 15 min. at room temperature. The resulting solution was combined with 7.0 gm (0.04 mole) of l-(2-hydroxyethoxy)ethylpiperazine, 9.7 gm (0.08 mole) of NN-dimethyl aniline. This reaction mixture was heated at gentle reflux for 40 hrs and the sample was analyzed by HPLC. The analysis revealed that starting material remains less than 1%. The reaction mixture was cooled to room temperature and treated with 175 cc IN hydrochloric acid solution to get a pH in between 1 to 2. The layers were separated and the aqueous layer was diluted with 100 cc toluene and pH was adjusted to about 8 to 9 with sodium carbonate. The layers were separated and aqueous layer was extracted with 100 cc toluene. The organic layers were combined and washed with 2 x 100 cc of water. The solvent was distilled under vacuum at 70°C to 80°C to afford 12 gm oil. HPLC area %: 96.52
Example-7: Preparation of ll-[4-[2-(2-Hydroxyethoxy)ethyl]-l- piperazinyl]dibenzo[b,fj[l,4]thiazepine
A 1 liter round bottom flask equipped with stirring rod, thermo pocket, reflux condenser and nitrogen inlet was charged with lOgm (0.04 moles) of 11- chlorodibenzo[b,f][l,4]-thiazepine, and 100 cc toluene and the mixture was stirred for 15 min. at room temperature. The resulting solution was combined with 7.0 gm
(0.04 mole) of l-(2-hydroxyethoxy)ethylpiperazine, 10.3 gm (0.08 mole) of N5N- diisopropyl ethyl aniline. This reaction mixture was heated at gentle reflux for 38 hrs and the sample was analyzed by HPLC. The analysis revealed that starting material remains less than 1%. The reaction mixture was cooled to room temperature and treated with 175 cc IN hydrochloric acid solution to get a pH in between 1 to 2. The layers were separated and the aqueous layer was diluted with 100 cc toluene and pH was adjusted to about 8 to 9 with sodium carbonate. The layers were separated and aqueous layer was extracted with lOOcc toluene. The organic layers were combined and washed with 2 x 100 cc of water. The solvent was distilled under vacuum at 70°C to 80°C to afford 12 gm oil. HPLC area %: 90.64
Example-8: Preparation of ll-[4-[2-(2-Hydroxyethoxy)ethyl]-l- piperazinyl]dibenzo[b,fj[l,4]thiazepine A l liter round bottom flask equipped with stirring rod, thermo pocket, reflux condenser and nitrogen inlet was charged with lOgm (0.04 moles) of 11- chlorodibenzo[b,f][l,4]-thiazepine,100 cc toluene and the mixture was stirred for 15 min. at room temperature. The resulting solution was combined with 7.0 gm (0.04 mole) of l-(2-hydroxyethoxy)ethylpiperazine, 8.0 gm (0.08 mole) of triethyl amine. This reaction mixture was heated at gentle reflux for 35 hrs and the sample was analyzed by HPLC. The analysis revealed that starting material remains less than 1%. The reaction mixture was cooled to room temperature and treated with 175 cc IN hydrochloric acid solution to get a pH in between 1 to 2. The layers were separated and the aqueous layer was combined with 100 cc toluene and pH was adjusted to about 8 to 9 by addition of sodium carbonate. The layers were separated and aqueous layer was extracted with 100 cc toluene. The organic layers were combined and washed with 2 x 100 cc of water. The solvent was distilled under vacuum at 70°C to 800C to afford 15 gm oil. HPLC area %: 97.7
Example-9: Preparation of ll-[4-[2-(2-Hydroxyethoxy)ethyl]-l- piperazinyl] dibenzo [b,fj [1 ,4] thiazepine
A 1 liter round bottom flask equipped with stirring rod, thermo pocket, reflux condenser and nitrogen inlet was charged with lOgm (0.04 moles) of 11- chlorodibenzo[&,/][l,4]-thiazepme, and 100 cc toluene and the mixture was stirred for
15 min. at room temperature. The resulting solution was treated with 7.0 gm (0.04 mole) of l-(2-hydroxyethoxy)ethylpiperazine, 6.7 gm (0.08 mole) of sodium bicarbonate. This reaction mixture was heated at gentle reflux for 35 hrs and the sample was analyzed by HPLC. The analysis revealed that starting material remains less than 1%. The reaction mixture was cooled to room temperature and treated with
175 cc IN hydrochloric acid solution to get a pH in between 1 to 2. The layers were separated and the aqueous layer was diluted with 100 cc toluene and pH was adjusted to about 8 to 9 with sodium carbonate. The layers were separated and the aqueous layer was extracted with 100 cc toluene. The organic layers were combined and washed with 2 x 100 cc of water. The solvent was distilled-off under vacuum at 7O0C to 80°C to afford 14 gm oil. HPLC area %: 94.68
Example-10: Preparation of ll-[4-[2-(2-Hydroxyethoxy)ethyI]-l- piperazinyl] dibenzo [b,fj [1 ,4] thiazepine A l liter round bottom flask equipped with stirring rod, thermo pocket, reflux condenser and nitrogen inlet was charged with lOgm (0.04 moles) of 11- chlorodibenzo[b,f][l,4]-thiazepine, and 100 cc toluene and the mixture was stirred for 15 min. at room temperature. The resulting solution was combined with 7.0 gm (0.04 mole) of l-(2-hydroxyethoxy)ethylpiperazine, 8.0 gm (0.08 mole) of potassium bicarbonate. This reaction mixture was heated at gentle reflux for 35 hrs and the sample was analyzed by HPLC. The analysis revealed that starting material remains less than 1% . The reaction mixture was cooled to room temperature and treated with 175 cc IN hydrochloric acid solution to get a pH in between 1 to 2. The layers were separated and the aqueous layer was diluted with 100 cc toluene and pH was adjusted to about 8 to 9 with sodium carbonate. The layers were separated and aqueous layer was extracted with 100 cc toluene. The organic layers were combined and washed with 2 x 100 cc of water. The solvent was distilled-off under vacuum at 70°C to 80°C to afford 15 gm oil. HPLC area %: 98.54
Example-11: Preparation of ll-[4-[2-(2-Hydroxyethoxy)ethyl]-l- piperazinyl]dibenzo[b,f][l,4]thiazepine
A 1 liter round bottom flask equipped with stirring rod, thermo pocket, reflux condenser and nitrogen inlet was charged with lOgm (0.04 moles) of 11- chlorodibenzo[b,fj[l,4]-thiazepine,100 cc toluene and the mixture was stirred for 15 min. at room temperature. The resulting solution was combined with 7.7gm (0.044 mole) of l-(2-hydroxyethoxy)ethylpiperazine, 8.5 gm (0.08 mole) of sodium carbonate and 7.7gm (0.026 mole) of tetra butyl ammonium bromide. This reaction mixture was heated at gentle reflux for 22 lirs and the sample was analyzed by HPLC. The analysis revealed that less than 1% of the starting material remained. The reaction mixture was cooled to room temperature and treated with 175 cc IN hydrochloric acid solution to get a pH in between 1 to 2. The layers were separated and the aqueous layer was extracted with 100 cc toluene and pH was adjusted to about 8 to 9 with sodium carbonate. The layers were separated and aqueous layer was extracted with 100 cc toluene. The organic layers were combined and washed with 2 x 100 cc of water. The solvent was distilled under vacuum at 70°C to 80°C to afford 12 gm oil. HPLC area %: 98.87
Example-12: Preparation of ll-[4-[2~(2-Hydroxyethoxy)ethyI]~l- piperazinyl]dibenzo[b,fj [l,4]thiazepine
A 1 liter round bottom flask equipped with stirring rod, thermo pocket, reflux condenser and nitrogen inlet was charged with lOgm (0.04 moles) of 11- chlorodibenzo[b,fj[l,4]-thiazepine,100 cc toluene and the mixture was stirred for 15 min. at room temperature. The resulting solution was combined with 7.7 gm (0.044 mole) of l-(2-hydroxyethoxy)ethylpiperazine, 8.5 gm (0.08 mole) of sodium carbonate and 4.0gm (0.02 mole) of trimethylsilyl iodide. This reaction mixture was heated at gentle reflux for 18 hrs and the sample was analyzed by HPLC. The analysis revealed that starting material remains less than 1% . The reaction mixture was cooled to room temperature and treated with 175 cc IN hydrochloric acid solution to get a pH in between 1 to 2. The layers were separated and the aqueous layer was diluted with 100 cc toluene and pH was adjusted between 8 to 9 with sodium carbonate. The layers were separated and aqueous layer was extracted with 100 cc toluene. The organic layers were combined and washed with 2 x 100 cc of water. The solvent was distilled under vacuum at 70°C to 80°C to afford 0.9 gm oil. HPLC area %: 98.9
Example 13: Preparation of ll-[4-[2-(2-Hydroxyethoxy)ethyl]-l- piperazinyl]dibenzo[b,fj[l,4]thiazepine fumarate
A 2 liter round bottom flask equipped with stirring rod, thermo pocket, reflux condenser and nitrogen inlet was charged with 50gm (0.2 moles) of 11- chlorodibenzo[b,f][l,4]-thiazepine (I), 500 cc toluene and the mixture was stirred for 15 min. at room temperature. The resulting solution was combined with 39 gm (0.22 mole) of l-(2-hydroxyethoxy)ethylpiperazine (II), 56.2 gm (0.40 mole) of potassium carbonate and 16.89 gm (0.10 mole) of potassium iodide. The reaction mixture was heated at gentle reflux for 12 hrs and a sample of the reaction mixture was analyzed by HPLC. The analysis revealed that less than 1% of the starting material remained . The reaction mixture was cooled to room temperature and combined with 1000 cc IN hydrochloric acid solution to get a pH in between 1 to 2. The layers were separated and the aqueous layer was diluted with 500 cc toluene and pH was adjusted to about 8 to 9 by addition of sodium carbonate. The layers (aqueous and nonaqueous reaction solvent toluene) were separated and the aqueous layer was extracted with 500 cc toluene. The organic (toluene) layers were combined and washed with 2 x 500 cc of water. The reaction solvent (toluene) was distilled-off under vacuum at 70 to 80° C, leaving 50 to 60cc toluene. To this solution 950 to 1000 cc absolute ethanol was added with activated carbon 5 to 6 gm and heated to reflux for 90 min. The mixture was then cooled to 55 to 60°C and filtered. The filtrate was further cooled to 25 to 300C, and fumaric acid 8 to 9 gm was added with stirring. The mixture was heated to reflux for 120 min, cooled slowly to 25 to 300C, maintained for 120 min, filtered, and washed with 175 to 200 cc absolute ethanol. The wet material obtained was dried under vacuum at 50 to 600C to produce quetiapine fumarate (50 to 55 gm).
Example 14: Preparation of ll-[4-[2-(2-Hydroxyethoxy)ethyl]-l- piperazinyl]dibenzo[b,f] [l,4]thiazepine fumarate
A 2 liter round bottom flask equipped with stirring rod, thermo pocket, reflux condenser and nitrogen inlet was charged with 50gm (0.2 moles) of 11- chlorodibenzo[b,f][l,4]-thiazepine (I) and 500 cc xylene and the mixture was stirred for 15 min. at room temperature. The resulting solution was combined with 39 gm (0.22 mole) of l-(2-hydroxyethoxy)ethylpiperazine, 56.2 gm (0.40 mole) of potassium carbonate and 16.89gm (0.10 mole) of potassium iodide. The reaction mixture was heated at gentle reflux for 12 hrs and a sample of the reaction mixture was analyzed by HPLC. The analysis revealed that less than 1% of starting material I remained. The reaction mixture was cooled to room temperature and treated with 1000 cc IN hydrochloric acid solution to get a pH in between 1 to 2. The layers were separated and the aqueous layer was agitated with 500 cc xylene and the pH was adjusted to about 8 to 9 by addition of sodium carbonate. The layers were separated and the aqueous layer was extracted with 500 cc xylene. The organic (xylene reaction solvent) layers were combined and washed with 2 x 500 cc of water. The solvent was distilled-off under vacuum at 70 to 80°C, leaving 50 to 60 cc. toluene. To this solution 950 to 1000 cc absolute ethanol was added with activated carbon 5 to 6 gm and heated to reflux for 90 min. The mixture was cooled to 55 to 60°C and filtered. The filtrate was further cooled to 25 to 30°C, and fumaric acid 8 to 9 gm was added with stirring. The mixture was heated to reflux for 120 min, cooled slowly to 25 to 30°C, maintained for 120 min, filtered, and washed with 175 to 200 cc. of absolute ethanol. The wet material obtained was dried under vacuum at 50 to 6O0C to produce quetiapine fumarate (50 to 55 gm).
Example 15: Preparation of ll-[4-[2-(2-Hydroxyethoxy)ethyl]-l- piperazinyl]dibenzo[b,f][l,4]thiazepine fumarate
A 2 liter round bottom flask equipped with stirring rod, thermo pocket, reflux condenser and nitrogen inlet was charged with 50gm (0.2 moles) of 11- chlorodibenzo[b,fj[l,4]-thiazepine and 500 cc n-butanol and the mixture was stirred for 15 min. at room temperature. The resulting solution was combined with 39 gm (0.22 mole) of l-(2-hydroxyethoxy)ethylpiperazine, 56.2 gm (0.40 mole) of potassium carbonate and 16.89gm (0.10 mole) of potassium iodide. The reaction mixture was heated at gentle reflux for 12 hrs and a sample of the reaction mixture was analyzed by HPLC. The analysis revealed that starting material remains less than 1%. The reaction mixture was cooled to room temperature and treated with 1000 cc IN hydrochloric acid solution to get a pH in between 1 to 2. The layers (aqueous and nonaqueous reaction solvent) were separated and the aqueous layer was extracted with 500 cc toluene and pH was adjusted to about 8 to 9 by addition of sodium carbonate. The layer s were separated and aqueous layer was again extracted with 500 cc toluene. The organic layers (n-butanol and toluene) were combined and washed with 2 x 500 cc of water. The solvent was distilled under vacuum at 70 to 80°C to obtain an oil. To this oil 50 to 75 cc. toluene was added with 750 to 1000 cc absolute ethanol and activated carbon 5 to 6 gm, and heated to reflux for 90 min. The mixture was cooled to 55 to 60°C and filtered. The filtrate was further cooled to 25 to 30°C and fumaric acid 7 to 7.5 gm was added with stirring. The mixture was heated to reflux for 120 min, cooled slowly to 25 to 30°C, maintained for 120 min, filtered, and washed with 125 to 150 cc. of absolute ethanol. The wet material obtained was dried under vacuum at 50 to 60°C to produce quetiapine fumarate (40 to 45 gm). Example 16: Preparation of ll-[4-[2-(2-Hydroxyethoxy)ethyl]-l- piperazinyl]dibenzo[b,f] [l,4]thiazepine fumarate
A 1 liter round bottom flask equipped with stirring rod, thermo pocket, reflux condenser and nitrogen inlet was charged with lOgm (0.04 moles) of 11- chlorodibenzo[b,fj[l,4]-thiazepine,100 cc toluene and the mixture was stirred for 15 min. at room temperature. The resulting solution was combined with 7.7 gm (0.044 mole) of l-(2-hydroxyethoxy)ethylpiperazine, 8.5 gm (0.08 mole) of sodium carbonate and 1.6 gm (0.01 mole) of sodium iodide. This reaction mixture was heated at gentle reflux for 15 hrs and the sample was analyzed by HPLC. The analysis revealed that starting material remains less than 1% . The reaction mixture was cooled to room temperature and treated with 175 cc IN hydrochloric acid solution to get a pH in between 1 to 2. The layers were separated and the aqueous layer was diluted with 100 cc toluene and pH was adjusted to about 8 to 9 with sodium carbonate. The layer s were separated and aqueous layer was extracted with 100 cc toluene. The organic layers were combined and washed with 2 x 100 cc of water. The solvent was distilled under vacuum at 70 to 80°C, leaving 10 to 15 cc toluene. To this solution 175 to 200 cc absolute ethanol was added with activated carbon 1 to 1.5 gm and heated to reflux for 90 min. The mixture was cooled to 55 to 60°C and filtered. The filtrate was further cooled to 25 to 30°C, and fumaric acid 1.5 to 2.0 gm was added with stirring. The mixture was heated to reflux for 120 min, cooled slowly to 25 to 3O0C, maintained for 120 min, filtered, and washed with 30 to 40 cc. of absolute ethanol. The wet material obtained was dried under vacuum at 50 to 6O0C to produce quetiapine fumarate (8 to 10 gm).
Example 17: Preparation of ll-[4-[2-(2-Hydroxyethoxy)ethyl]-l- piperazmyl]dibenzo[b,f][l,4]thiazepine
A 1 liter round bottom flask equipped with stirring rod, thermo pocket, reflux condenser and nitrogen inlet was charged with lOgm (0.04 moles) of 11- chlorodibenzo[b,fj[l,4]-thiazepine (I), 100 cc toluene and the mixture was stirred for 15 min. at room temperature. The resulting solution was combined with 7.7 gm (0.044 mole) of l-(2-hydroxyethoxy)ethylpiperazine (II), 8.5 gm (0.08 mole) of sodium carbonate carbonate and 7.7gm (0.24 mole) of tetra butyl ammonium bromide. The reaction mixture was heated at gentle reflux for 22 hrs and a sample of the reaction mixture was analyzed by HPLC. The analysis revealed that less than 2% of the starting material remained. The reaction mixture was cooled to room temperature and combined with 300 cc IN hydrochloric acid solution to get a pH in between 1 to 2. The layers were separated and the aqueous layer was diluted with 100 cc toluene and pH was adjusted between 8 to 9 by addition of sodium carbonate. The layers (aqueous and nonaqueous reaction solvent toluene) were separated and the aqueous layer was extracted with 100 cc toluene. The organic (toluene) layers were combined and washed with 2 x 100 cc of water. The reaction solvent (toluene) was distilled-off under vacuum at 70 to 800C to afford 12 gm oil. HPLC area %: 98.87
EXAMPLE 18
[0001] Example 18: Preparation of l l-[4-[2-(2-Hydroxyethoxy)ethyl]-l- piperazinyl] dibenzo [b,fj [ 1 ,4]thiazepine
[0002] A 2 liter round bottom flask equipped with stirring rod, thermo pocket, reflux condenser and nitrogen inlet was charged with 50gm (0.2 moles) of 11- chlorodibenzo[b,f][l,4]-thiazepine (I), 500 cc toluene and the mixture was stirred for 15 min. at room temperature. The resulting solution was combined with 39 gm (0.22 mole) of l-(2-hydroxyethoxy)ethylρiperazine (II), 56.2 gm (0.40 mole) of potassium carbonate and 16.89gm (0.10 mole) of potassium iodide. The reaction mixture was heated at gentle reflux for 12 hrs and a sample of the reaction mixture was analyzed by HPLC. The analysis revealed that less than 1% of the starting material remained. The reaction mixture was cooled to room temperature and combined with 1000 cc IN hydrochloric acid solution to get a pH in between 1 to 2. The layers were separated and the aqueous layer was diluted with 500 cc toluene and pH was adjusted between 8 to 9 by addition of sodium carbonate. The layers (aqueous and nonaqueous reaction solvent toluene) were separated and the aqueous layer was extracted with 500 cc toluene. The organic (toluene) layers were combined and washed with 2 x 500 cc of water. The reaction solvent (toluene) was distilled-off under vacuum at 70 to 80°C to afford 60 gm oil. The above oil is crystallized using ethyl acetate to afford 11-[4-[2- (2-Hydroxyethoxy)ethyl]-l-piperazinyl]dibenzo[b,fJ[l,4]thiazepine 55 gm.

Claims

WHAT CLAIMED IS:
1. A method for preparing quetiapine, 11 -[4-[2-(2-hydroxyethoxy)ethyl]- l-piperazinyl]dibenzo[fr/][l,4]thiazepine comprising the steps of: combining l l-chlorodibenzo[δ,/j[l,4]thiazepine (I), about 1 to about 1.5 molar equivalents with respect to (I) l-(2-hydroxyethoxy)ethyl piperazine (II),
Figure imgf000024_0001
I II a base, and a halide that is either an alkali metal halide or a silylhalide in a reaction solvent to obtain a reaction mixture, and heating the reaction mixture at a reaction temperature from about room temperature to reflux temperature for a reaction time. 2. The method of claim 1 , wherein the molar amount of 1 -(2- hydroxyethoxy)ethyl piperazine (II) is about 1 to about 1.
2 molar equivalents with respect to 1 l-chlorodibenzo[έ,/][l,4]thiazepine (I).
3. The method of any preceding claim wherein the reaction temperature is reflux temperature.
4. The method of any preceding claim wherein the base is an organic base that is an amine.
5. The method of claim 4 wherein the amine is a tertiary amine.
6. The method of claim 1 wherein the base is an inorganic base that is an alkali metal carbonate, bicarbonate, or hydroxide.
7. The method of claim 6, wherein the inorganic base is selected from the group consisting of potassium bicarbonate, sodium bicarbonate, and sodium hydroxide.
8. The method of claim 6 wherein the base is an alkali metal carbonate that is potassium carbonate.
9. The method of any preceding claim wherein the base is used in a molar amount between about 1 and about 3 molar equivalents with respect to the molar amount of 1 l-chlorodibenzo[δ,/J[l,4]thiazepine (I) used in the reaction.
10. The method of claim 9 wherein the base is used in a molar amount of about 2 molar equivalents with respect to the molar amount of 11- chlorodibenzo [b,f\ [ 1 ,4]thiazepine (I).
11. The method of any preceding claim wherein the halide is an alkali metal fluoride, iodide, or bromide.
12. The method of claim 11 wherein the alkali metal halide is an alkali metal iodide.
13. The method of claim 12 wherein the alkali metal iodide is potassium iodide.
14. The method of any preceding claim wherein the halide is used in a molar ratio of at least about 0.2 relative to the moles of 11- chlorodibenzo [b,f\ [ 1 ,4]thiazepine (I) used.
15. The method of any preceding claim wherein the reaction solvent is a non- halogenated aromatic hydrocarbon, an alkyl ester, a mixture of a non- halogenated aromatic hydrocarbon and an alkyl ester, or an alkyl alcohol.
16. The method of claim 15 wherein the reaction solvent is toluene or xylene or a mixture thereof.
17. The method of claim 15 wherein the reaction solvent is an alkyl alcohol or a mixture of alkyl alcohols.
18. The method of any preceding claim wherein the reaction time is about 20 hours or less.
19. The method of claim 1 wherein the reaction time is about 10 to about 14 hours.
20. The method of any preceding claim wherein the reaction time is monitored by the disappearance of compound I using thin layer chromatography, gas-liquid chromatography, or high pressure liquid chromatography.
21. The method of any preceding claim further comprising the step of converting the quetiapine to a pharmaceutically acceptable salt.
22. The method of claim 21 wherein the pharmaceutically acceptable salt is quetiapine fumarate or quetiapine hemifumarate and wherein the conversion is effected by combining fumaric acid with the quetiapine.
23. The method of claim 21 wherein the quetiapine is combined with the fumaric acid in a solvent that is either the reaction solvent or a salification solvent.
24. The method of claim 23 wherein the combining is in the reaction solvent and the quetiapine is not isolated from said reaction solvent prior to combination with fumaric acid.
25. The method of claim 23, wherein the solvent is a salification solvent that is one or more aromatic hydrocarbons, or one or more C1 to C4 alcohol.
26. The method of claim 25 wherein the salification solvent is toluene or ethanol.
27. The method in claim 24 wherein, prior to combination with fumaric acid, the quetiapine in the reaction solvent is heated to about reflux temperature and subsequently cooled to about 300C to about 60°C, whereafter the fumaric acid is combined.
28. The use of a process according to any preceding claim in the manufacture of quetiapine or a pharmaceutically acceptable salt thereof.
29. Use according to claim28 wherein the pharmaceutically acceptable salt is a fumarate salt.
PCT/US2006/014049 2005-04-14 2006-04-14 Process for preparing quetiapine fumarate WO2006113425A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US67217505P true 2005-04-14 2005-04-14
US60/672,175 2005-04-14
US67709105P true 2005-05-02 2005-05-02
US60/677,091 2005-05-02
US68014005P true 2005-05-11 2005-05-11
US60/680,140 2005-05-11

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002603795A CA2603795A1 (en) 2005-04-14 2006-04-14 Process for preparing quetiapine fumarate
EP06740948A EP1869007A1 (en) 2005-04-14 2006-04-14 Process for preparing quetiapine fumarate
JP2007516862A JP2008502707A (en) 2005-04-14 2006-04-14 Method for preparing quetiapine fumarate

Publications (1)

Publication Number Publication Date
WO2006113425A1 true WO2006113425A1 (en) 2006-10-26

Family

ID=36688015

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/014049 WO2006113425A1 (en) 2005-04-14 2006-04-14 Process for preparing quetiapine fumarate

Country Status (5)

Country Link
US (1) US7687622B2 (en)
EP (1) EP1869007A1 (en)
JP (1) JP2008502707A (en)
CA (1) CA2603795A1 (en)
WO (1) WO2006113425A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008152434A1 (en) * 2007-06-12 2008-12-18 Richter Gedeon Nyrt. Synthesis for the preparation of quetiapine
US7687622B2 (en) 2005-04-14 2010-03-30 Teva Pharmaceutical Industries, Ltd Process for preparing quetiapine fumarate
WO2010100623A1 (en) 2009-03-04 2010-09-10 Ranbaxy Laboratories Limited Process for the preparation of quetiapine fumarate
US8420807B2 (en) 2008-01-31 2013-04-16 Fermion Oy Process for the preparation of quetiapine

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003235435A1 (en) * 2002-03-20 2003-10-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
WO2008121415A2 (en) * 2007-03-29 2008-10-09 Teva Pharmaceutical Industries Ltd. Improved process for preparing quetiapine fumarate
CN101676275B (en) * 2008-09-17 2014-05-07 北京德众万全药物技术开发有限公司 preparation method of quetiapine fumarate
JP2017529952A (en) 2014-10-03 2017-10-12 ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. System and method for neural stimulation therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240228A1 (en) * 1986-03-27 1987-10-07 Ici Americas Inc. Thiazepine compounds
WO2004076431A1 (en) * 2003-02-22 2004-09-10 Teva Pharmaceutical Industries Ltd. Synthesis of quetiapine and pharmaceutically acceptable salts thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3188323A (en) * 1963-02-12 1965-06-08 Olin Mathieson Dihydrodibenzothiazepines
US4115292A (en) * 1977-04-20 1978-09-19 The Procter & Gamble Company Enzyme-containing detergent articles
DE3621536A1 (en) * 1986-06-27 1988-01-07 Henkel Kgaa LIQUID DETERGENT AND METHOD FOR THE PRODUCTION THEREOF
GB8705574D0 (en) 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
GB9716161D0 (en) * 1997-08-01 1997-10-08 Zeneca Ltd Process
GB9812413D0 (en) * 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
AT258777T (en) * 1999-07-02 2004-02-15 Cognis Iberia Sl MICROCAPSULES - II
DE59912559D1 (en) * 1999-07-02 2005-10-20 Cognis Ip Man Gmbh Microcapsules - III
AT258417T (en) * 1999-07-02 2004-02-15 Cognis Iberia Sl MICROCAPSULES - I
IL147379D0 (en) * 1999-07-09 2002-08-14 Ube Industries Process for preparing dibenzothiazepine derivatives
AU6476300A (en) * 1999-09-30 2001-05-10 Sumika Fine Chemicals Co., Ltd. Process for the preparation of a piperazine derivative
HU227039B1 (en) 2000-01-25 2010-05-28 Egis Gyogyszergyar Nyilvanosan New process for the production of quetiapine and intermediates therefor
DE50011907D1 (en) * 2000-03-04 2006-01-26 Cognis Ip Man Gmbh microcapsules
US6794467B2 (en) * 2000-03-27 2004-09-21 Council Of Scientific And Industrial Research Process for the preparation of polymeric absorbents
WO2002057402A1 (en) 2001-01-19 2002-07-25 The Procter & Gamble Company Liquid composition in a pouch
AU2003235435A1 (en) * 2002-03-20 2003-10-08 Teva Pharmaceutical Industries Ltd. Crystalline forms of quetiapine hemifumarate
KR100707050B1 (en) 2002-11-28 2007-04-13 에스케이 주식회사 Method of preparing 10H-Dibenzo[b,f][1,4]thiazepine-11-one
TR200503401T1 (en) * 2003-03-03 2008-03-21 Hetero Drugs Limited Quetiapine new polymorphs of Fumarate
MXPA05013869A (en) * 2003-07-02 2006-02-28 Astrazeneca Ab Metabolite of quetiapine.
PL195728B1 (en) 2003-07-18 2007-10-31 Helm Ag Method for manufacture of 11-(1-piperazinyl)dibenzo[b,f][1,4]thiazepine
EP1654249A1 (en) * 2003-08-07 2006-05-10 Pharmacia & Upjohn Company LLC Anthelmintic and insecticide pyrimidine derivatives
ES2223294B2 (en) * 2003-08-08 2005-10-01 Vita Cientifica, S.L. PREPARATION PROCEDURE FOR A PHARMACEUTICALLY ACTIVE COMPOUND.
US20050080072A1 (en) * 2003-09-01 2005-04-14 Orchid Chemicals & Pharmaceuticals Ltd. Process for the preparation of a thiazepine derivative
WO2005028457A1 (en) 2003-09-23 2005-03-31 Fermion Oy Preparation of quetiapine
EP1664009B1 (en) 2003-09-23 2011-01-19 Fermion Oy Preparation method for quetiapine
PT1664007E (en) 2003-09-23 2010-02-15 Fermion Oy Preparation of quetiapine
NZ547911A (en) * 2003-12-22 2010-06-25 Acadia Pharm Inc Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
PL368245A1 (en) 2004-05-28 2005-12-12 CELON PHARMA Sp.z o.o. Method for manufacture of quetiapine
KR101038389B1 (en) * 2004-06-23 2011-06-01 에스케이바이오팜 주식회사 Process for the preparation of 11-4-[2-2-hydroxyethoxyethyl]-1-piperazinyldibenzo[b,f][1,4]thiazepine
WO2006027789A1 (en) 2004-09-08 2006-03-16 Jubilant Organosys Limited PROCESS FOR PRODUCING 11-[4-[2-(2-HYDROXYETHOXY)ETHYL]-1-PIPERAZINYL]DIBENZO[b,f][1,4]THIAZEPINE AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
US20060063927A1 (en) * 2004-09-22 2006-03-23 Olga Etlin Processes for preparing quetiapine and salts thereof
WO2006035293A1 (en) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Polymorphic forms of quetiapine hemifumarate
WO2006056772A2 (en) 2004-11-23 2006-06-01 Pliva Hrvatska D.O.O. Salts of quetiapine
GB0425729D0 (en) 2004-11-23 2004-12-22 Pliva Res & Dev Ltd Heterocyclic compounds
WO2006077602A1 (en) 2005-01-24 2006-07-27 Ipca Laboratories Limited INDUSTRIAL PREPARATION OF 11-[4-{2-(2-HYDROXYETHOXY ETHYL}-1-PIPERAZINYL] DIBENZO [b,f]-1[1, 4] THIAZEPINE
ES2234447B1 (en) 2005-03-07 2006-03-01 Union Quimico-Farmaceutica S.A. PROCEDURE FOR OBTAINING A DERIVATIVE OF 11- (4-SUBSTITUTED-1-PIPERAZINIL) DIBENZO (B, F) (1,4) THIAZEPINE.
US7488821B2 (en) * 2005-04-04 2009-02-10 Divi's Laboratories Limited Polymorph of Quetiapine fumarate and a process for its preparation
WO2006113425A1 (en) 2005-04-14 2006-10-26 Teva Pharmaceutical Industries Ltd. Process for preparing quetiapine fumarate
EP1879874A2 (en) 2005-04-21 2008-01-23 Medichem, S.A. Process for preparing quetiapine and quetiapine fumarate
WO2006135544A1 (en) 2005-06-10 2006-12-21 Cambrex Charles City, Inc. SYNTHESIS OF 11-(4[-(2-HYDROXYETHOXY)ETHYL]-PIPERAZINYL)-DIBENZO[b,f][1,4]THIAZEPINE AND ITS FUMARATE SALT
WO2007004234A1 (en) 2005-07-04 2007-01-11 Usv Limited A PROCESS FOR THE PREPARATION OF 2-[2-(4-DIBENZO[b,f] [L,4] THIAZEPIN-11-yl-1- PIPERAZINYL)ETHOXY] ETHANOL FUMARATE
GB0516603D0 (en) 2005-08-12 2005-09-21 Sandoz Ag Processes for the preparation of organic compounds useful as serotonin receptor antagonists
WO2007036599A1 (en) 2005-09-30 2007-04-05 Fermion Oy New crystallization process of quetiapine hemifumarate
US8044039B2 (en) 2005-10-28 2011-10-25 Fermion Oy Quetiapine hemifumarate purification by crystallization
CN101360502B (en) 2005-11-18 2012-03-14 阿斯利康公司 Crystalline forms
BRPI0708096A2 (en) 2006-02-22 2011-05-17 Astrazeneca Uk Ltd method to prepare a compound
WO2007102074A2 (en) 2006-03-07 2007-09-13 Cadila Healthcare Limited Salts of quetiapine
CZ300451B6 (en) 2006-07-03 2009-05-20 Farmak, A. S. Process for preparing salts of 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]ethanol (quetiapine) and purification process of such salts
CN100569761C (en) 2007-04-18 2009-12-16 湖南洞庭药业股份有限公司 The production method of preparation pharmaceutical purity quetiapine fumarate
CN101293879A (en) 2008-06-24 2008-10-29 广东肇庆星湖生物科技股份有限公司 Method for preparing quetiapin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0240228A1 (en) * 1986-03-27 1987-10-07 Ici Americas Inc. Thiazepine compounds
US4879288A (en) 1986-03-27 1989-11-07 Ici Americas Inc. Novel dibenzothiazepine antipsychotic
WO2004076431A1 (en) * 2003-02-22 2004-09-10 Teva Pharmaceutical Industries Ltd. Synthesis of quetiapine and pharmaceutically acceptable salts thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WARAWA E J ET AL: "Behavioral approach to nondyskinetic dopamine antagonists: Identification of Seroquel", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 44, 1 February 2001 (2001-02-01), pages 372 - 389, XP002213291, ISSN: 0022-2623 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7687622B2 (en) 2005-04-14 2010-03-30 Teva Pharmaceutical Industries, Ltd Process for preparing quetiapine fumarate
WO2008152434A1 (en) * 2007-06-12 2008-12-18 Richter Gedeon Nyrt. Synthesis for the preparation of quetiapine
US8420807B2 (en) 2008-01-31 2013-04-16 Fermion Oy Process for the preparation of quetiapine
WO2010100623A1 (en) 2009-03-04 2010-09-10 Ranbaxy Laboratories Limited Process for the preparation of quetiapine fumarate

Also Published As

Publication number Publication date
JP2008502707A (en) 2008-01-31
EP1869007A1 (en) 2007-12-26
US20060276641A1 (en) 2006-12-07
CA2603795A1 (en) 2006-10-26
US7687622B2 (en) 2010-03-30

Similar Documents

Publication Publication Date Title
EP1869007A1 (en) Process for preparing quetiapine fumarate
US7071331B2 (en) Synthesis of quetiapine and pharmaceutically acceptable salts thereof
US20060063927A1 (en) Processes for preparing quetiapine and salts thereof
WO2007020011A1 (en) Processes for the preparation of thiazepines
EP1660468B1 (en) Procedure for preparing 11-(4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl)-dibenzo[b,f][1,4]thiazepine
WO2010097805A1 (en) A process for the preparation of ranolazine
US20090156802A1 (en) Quetiapine Hemifumarate Purification by Crystallization
US7847094B2 (en) Industrial preparation of 11-[4-{2-(2-hydroxyethoxy) ethyl}-1-piperazinyl] dibenzo [b,f]-[1,4]thiazepine
EP2421843B1 (en) Process for the preparation of olopatadine
WO2012153341A1 (en) A process for the preparation of iloperidone and pharmaceutically acceptable salts thereof
US8420807B2 (en) Process for the preparation of quetiapine
WO2008121415A2 (en) Improved process for preparing quetiapine fumarate
CA2937417C (en) An improved process for the preparation of trazodone and hydrochloride salt thereof
US8389716B2 (en) Process for the synthesis of quetiapine
WO2010046908A2 (en) Novel water based process for the preparation of substituted diphenylmethyl piperazines
CN101198599A (